Stock Research: OSE Immunotherapeutics

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

OSE Immunotherapeutics

PAR:OSE FR0012127173
73
  • Value
    83
  • Growth
    32
  • Safety
    Safety
    95
  • Combined
    100
  • Sentiment
    81
  • 360° View
    360° View
    73
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

ANALYSIS: With an Obermatt 360° View of 73 (better than 73% compared with alternatives), overall professional sentiment and financial characteristics for the stock OSE Immunotherapeutics are above average. The 360° View is based on consolidating four consolidated indicators, with half of the indicators below and half above average for OSE Immunotherapeutics. The consolidated Value Rank has an attractive rank of 83, which means that the share price of OSE Immunotherapeutics is on the lower side compared with typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 83% of alternative stocks in the same industry. The company is also safely financed with a Safety rank of 95. In addition, professional market sentiment is above average compared with other stock investment alternatives with a Sentiment Rank of 81. But the consolidated Growth Rank has a low rank of 32, which means that the company is below average in terms of growth and momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. 68 of its competitors have better growth. ...read more

more
Index
CAC All
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 13-Mar-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
83 n/a n/a n/a
Growth
32 n/a n/a n/a
Safety
Safety
95 n/a n/a n/a
Sentiment
81 n/a n/a n/a
360° View
360° View
73 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
100 n/a n/a n/a
Opinions Change
50 n/a n/a n/a
Pro Holdings
n/a n/a n/a n/a
Market Pulse
73 n/a n/a n/a
Sentiment
81 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
83 n/a n/a n/a
Growth
32 n/a n/a n/a
Safety Safety
95 n/a n/a n/a
Combined
100 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
92 n/a n/a n/a
Price vs. Earnings (P/E)
67 n/a n/a n/a
Price vs. Book (P/B)
45 n/a n/a n/a
Dividend Yield
1 n/a n/a n/a
Value
83 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
14 n/a n/a n/a
Profit Growth
68 n/a n/a n/a
Capital Growth
69 n/a n/a n/a
Stock Returns
11 n/a n/a n/a
Growth
32 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
33 n/a n/a n/a
Refinancing
20 n/a n/a n/a
Liquidity
92 n/a n/a n/a
Safety Safety
95 n/a n/a n/a

Similar Stocks

Discover high‑ranked alternatives to OSE Immunotherapeutics and broaden your portfolio horizons.

Michelin

PAR:ML
Country: France
Industry: Tires & Rubber
Size: X-Large
Full Stock Analysis

Grifols

MCE:GRF
Country: Spain
Industry: Biotechnology
Size: X-Large
Full Stock Analysis

Rubis

PAR:RUI
Country: France
Industry: Gas Utilities
Size: Large
Full Stock Analysis

Societe Generale

PAR:GLE
Country: France
Industry: Diversified Banks
Size: Medium
Full Stock Analysis

Frequently Asked
Questions

The stock offers good value, safe financing, and positive sentiment. However, it has below-average growth expectations. It is well-suited for conservative buy-and-hold investors who prioritize stability and low valuation over growth.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing: